tirzepatide cardiovascular outcome Real-World Outcomes of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF A comparison of the effects

The Phase 2 trial used 4-week intervals between increases, and groups that followed dose escalation had better tolerability than those started at fixed higher doses

Have you started a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Saxenda and noticed changes in your skin

Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement

Maintain a balanced diet and regular exercise routine to support overall hormonal health